Apple’s latest iPhone release has investors asking if now is the right time to buy. While some analysts see potential growth, others remain cautious about the tech giant’s immediate prospects. Opinions vary widely across the market.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has seen its projected earnings for 2026 revised downward. According to Leerink Partnrs’ recent report, the biotech company’s EPS forecast now stands at ($4.05) for fiscal year 2026.
Analysts at Wedbush project that Telix Pharmaceuticals could achieve an earnings per share of $0.89 by 2028. The research note, released on August 21st, underscores the potential growth trajectory for the pharmaceutical company in the coming years.
As V2X gears up to release its quarterly earnings on May 5th, analysts are forecasting promising results with earnings per share projected at $0.91 and revenue expected to reach $1.04 billion.
Shares of Colruyt Group have plummeted to a 52-week low of $9.50, signaling significant shifts in the European retail market. With stock prices falling below key moving averages, investors are keenly observing the company’s financial health and market position.
